Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure

Journal of Cardiology

Volumn 60, Issue 6, 2012, Pages 462-469

  Watanabe, Kiyotaka ^a   Dohi, Kaoru ^a   Sugimoto, Tadafumi ^a   Yamada, Tomomi ^a   Sato, Yuichi ^a   Ichikawa, Kazuhide ^a   Sugiura, Emiyo ^a   Kumagai, Naoto ^a   Nakamori, Shiro ^a   Nakajima, Hiroshi ^a   Hoshino, Kozo ^b   Machida, Hirofumi ^c   Okamoto, Shinya ^d   Onishi, Katsuya ^a   Nakamura, Mashio ^a   Nobori, Tsutomu ^a   Ito, Masaaki ^a  

^a MIE UNIVERSITY   (Japan)

^b Nagai Hospital   (Japan)

^c Takeuchi Hospital   (Japan)

^d Iwasaki Hospital   (Japan)

Author keywords

Diuresis; Heart failure; Hemodynamics; Vasopressin V2 receptor antagonist

Indexed keywords

ALDOSTERONE; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BILIRUBIN; BRAIN NATRIURETIC PEPTIDE; CREATININE; ELECTROLYTE; HEMOGLOBIN; LOOP DIURETIC AGENT; NEUROHORMONE; POTASSIUM; SERUM ALBUMIN; SODIUM; THIAZIDE DIURETIC AGENT; TOLVAPTAN;

AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FEMALE; FLUID INTAKE; FLUID RETENTION; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERNATREMIA; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MALE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; SERUM OSMOLALITY; SHORT COURSE THERAPY; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; WEIGHT REDUCTION;

AGED; BENZAZEPINES; BODY FLUIDS; BODY WEIGHT; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PULMONARY CIRCULATION; RECEPTORS, VASOPRESSIN; SODIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; URINE; VASCULAR RESISTANCE;

EID: 84869089049     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.09.002     Document Type: Article

References (24)

1. Kuwahata S., Miyata M., Fujita S., Kubozono T., Shinsato T., Ikeda Y., Hamasaki S., Kuwaki T., Tei C. Improvement of autonomic nervous activity by Waon therapy in patients with chronic heart failure. J Cardiol 2011, 57:100-106.
2. Nishi K., Sato Y., Miyamoto T., Toma M., Taniguchi R., Fukuhara R., Saijo S., Fujiwara H., Takatsu Y. Intermittent infusions of carperitide or inotoropes in out-patients with advanced heart failure. J Cardiol 2012, 59:366-373.
3. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., Oates J.A., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
4. Hiramitsu S., Miyagishima K., Kimura H., Mori K., Shiino K., Yamada A., Kato S., Kato Y., Morimoto S., Hishida H., Ozaki Y. Management of severe heart failure. Circ J 2009, 73(Suppl. A):A36-A41.
5. Miyata M., Sasaki T., Ikeda Y., Shinsato T., Kubozono T., Furusho Y., Kusumoto A., Hamasaki S., Tei C., COLD-CHF Investigators Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF). J Cardiol 2012, 59:352-358.
6. Gupta S., Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J 2005, 26:644-649.
7. Stevenson L.W., Tillisch J.H. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation 1986, 74:1303-1308.
8. Matsuzaki M., Hori M., Izumi T., Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011, 25(Suppl. 1):S33-S45.
9. Yamamura Y., Nakamura S., Itoh S., Hirano T., Onogawa T., Yamashita T., Yamada Y., Tsujimae K., Aoyama M., Kotosai K., Ogawa H., Yamashita H., Kondo K., Tominaga M., Tsujimoto G., et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998, 287:860-867.
10. Gheorghiade M., Niazi I., Ouyang J., Czerwiec F., Kambayashi J., Zampino M., Orlandi C. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107:2690-2696.
11. Costello-Boerrigter L.C., Smith W.B., Boerrigter G., Ouyang J., Zimmer C.A., Orlandi C., Burnett J.C. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006, 290:F273-F278.
12. Inomata T., Izumi T., Matsuzaki M., Hori M., Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011, 25(Suppl. 1):S57-S65.
13. Stanek B., Frey B., Hulsmann M., Berger R., Sturm B., Strametz-Juranek J., Bergler-Klein J., Moser P., Bojic A., Hartter E., Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001, 38:436-442.
14. Gheorghiade M., Konstam M.A., Burnett J.C., Grinfeld L., Maggioni A.P., Swedberg K., Udelson J.E., Zannad F., Cook T., Ouyang J., Zimmer C., Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297:1332-1343.
15. Matsuzaki M., Hori M., Izumi T., Asanoi H., Tsutamoto T. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther 2011, 25(Suppl. 1):S19-S31.
16. Filep J., Rosenkranz B. Mechanism of vasopressin-induced platelet aggregation. Thromb Res 1987, 45:7-15.
17. Robertson G.L. Thirst and vasopressin function in normal and disordered states of water balance. J Lab Clin Med 1983, 101:351-371.
18. Onogawa T., Sakamoto Y., Nakamura S., Nakayama S., Fujiki H., Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther 2011, 25(Suppl. 1):S67-S76.
19. Udelson J.E., Bilsker M., Hauptman P.J., Sequeira R., Thomas I., O'Brien T., Zimmer C., Orlandi C., Konstam M.A. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail 2011, 17:973-981.
20. Udelson J.E., Orlandi C., Ouyang J., Krasa H., Zimmer C.A., Frivold G., Haught W.H., Meymandi S., Macarie C., Raef D., Wedge P., Konstam M.A., Gheorghiade M. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008, 52:1540-1545.
21. Kee K., Naughton M.T. Heart failure and the lung. Circ J 2010, 74:2507-2516.
22. Walker B.R., Haynes J., Wang H.L., Voelkel N.F. Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol 1989, 257:H415-H422.
23. Thibonnier M., Preston J.A., Dulin N., Wilkins P.L., Berti-Mattera L.N., Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 1997, 138:4109-4122.
24. Smith A.M., Elliot C.M., Kiely D.G., Channer K.S. The role of vasopressin in cardiorespiratory arrest and pulmonary hypertension. QJM 2006, 99:127-133.